MX348663B - Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009. - Google Patents

Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.

Info

Publication number
MX348663B
MX348663B MX2009009565A MX2009009565A MX348663B MX 348663 B MX348663 B MX 348663B MX 2009009565 A MX2009009565 A MX 2009009565A MX 2009009565 A MX2009009565 A MX 2009009565A MX 348663 B MX348663 B MX 348663B
Authority
MX
Mexico
Prior art keywords
outbreak
against influenza
escherichia coli
influenza
protein
Prior art date
Application number
MX2009009565A
Other languages
English (en)
Other versions
MX2009009565A (es
Inventor
Ismael Mendoza Ochoa Gonzalo
Moisés ALVAREZ Mario
Manuel Aguilar Yañez José
Ángel GARCÍA ECHAURI Sergio
Portillo Lara Roberto
Original Assignee
Inst Tecnologico Estudios Superiores Monterrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Tecnologico Estudios Superiores Monterrey filed Critical Inst Tecnologico Estudios Superiores Monterrey
Priority to MX2009009565A priority Critical patent/MX348663B/es
Publication of MX2009009565A publication Critical patent/MX2009009565A/es
Priority to PCT/MX2010/000027 priority patent/WO2011031125A1/es
Publication of MX348663B publication Critical patent/MX348663B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una vacuna recombinante expresable en cepas de Escherichia coli caracterizada por contener la Sec ID No. 1 del fragmento no glicosilado de la hemaglutinina del virus de la Influenza A H1N1/2009, con un extremo N-terminal de 3 a 12 histidinas (Sec. ID No. 2 y la secuencia Sec ID No.3).
MX2009009565A 2009-09-08 2009-09-08 Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009. MX348663B (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2009009565A MX348663B (es) 2009-09-08 2009-09-08 Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.
PCT/MX2010/000027 WO2011031125A1 (es) 2009-09-08 2010-03-26 Proteínas recombinantes expresables en escherichia coli como ingredientes activos de vacunas contra influenza a h1n1 brote 2009 y su proceso de producción

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2009009565A MX348663B (es) 2009-09-08 2009-09-08 Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.

Publications (2)

Publication Number Publication Date
MX2009009565A MX2009009565A (es) 2009-11-10
MX348663B true MX348663B (es) 2017-05-26

Family

ID=42025992

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009565A MX348663B (es) 2009-09-08 2009-09-08 Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.

Country Status (2)

Country Link
MX (1) MX348663B (es)
WO (1) WO2011031125A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005319141B8 (en) * 2004-12-21 2010-03-18 Vaxinnate Corporation Compositions of influenza viral proteins and methods of use thereof

Also Published As

Publication number Publication date
MX2009009565A (es) 2009-11-10
WO2011031125A1 (es) 2011-03-17

Similar Documents

Publication Publication Date Title
CN103732749B (zh) 计算优化的宽反应性的h1n1流感抗原
NZ701881A (en) Vaccines for hsv-2
US10736956B2 (en) Influenza virus vaccination regimens
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
RS20080174A (en) Canine influenza virus and related compositions and methods of use
WO2011143262A3 (en) Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
KR20140099515A (ko) 인플루엔자 바이러스 백신 및 이의 용도
NZ596032A (en) Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
BR112013026706A2 (pt) composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
KR20100067094A (ko) 인플루엔자 항원 수송 벡터 및 구조물
NZ627888A (en) Materials and methods for respiratory disease control in canines
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
US11304989B2 (en) Peptides for use in the treatment of viral infections
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
GB201303983D0 (en) Drug and method for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including AIDS
JP5343079B2 (ja) トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法
Jazi et al. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine
WO2012054907A3 (en) Novel hemagglutinin 5 (h5) proteins for the treatment and prevention of influenza infections
NZ712713A (en) Attenuated swine influenza vaccines and methods of making and use thereof
JP2013504519A5 (es)
PE20121553A1 (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una efermedad parasitaria
BR112014007491A2 (pt) sequências de aminoácidos para o controle de patógenos
MX348663B (es) Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.

Legal Events

Date Code Title Description
FG Grant or registration